Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study
Crossref DOI link: https://doi.org/10.1186/s13075-017-1264-6
Published Online: 2017-03-14
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tanaka, Yoshiya
Yamanaka, Hisashi
Ishiguro, Naoki
Miyasaka, Nobuyuki
Kawana, Katsuyoshi
Kimura, Junko
Agata, Naoki
Takeuchi, Tsutomu